Research programme: E3 ubiquitin ligase inhibitors - Apeiron Biologics

Drug Profile

Research programme: E3 ubiquitin ligase inhibitors - Apeiron Biologics

Alternative Names: APN-411

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; Evotec AG
  • Class Small molecules
  • Mechanism of Action CBLB protein expression modulators; Gene transference; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Cancer
  • No development reported Solid tumours

Most Recent Events

  • 31 Aug 2016 APN 411 is in preclinical trials for Cancer in Austria (Apeiron Biologics pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top